Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Meta Expands AI Training With Employee Activity Tracking Tools 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
IRVINE, Calif., March 30, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq:STML). Investors who purchased shares of the Company either (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”) are encouraged to contact the Firm prior to the April 4, 2017 lead plaintiff motion deadline.
If you purchased shares of Stemline during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, Stemline made false and/or misleading statements and/or failed to disclose that a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and thus, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. On February 2, 2017, Bloomberg disclosed that a patient in a clinical trial of Stemline’s cancer drug SL-401 died from a side effect. This is the third death linked to SL-401 toxicity. When this information was announced to the public, the value of Stemline stock fell significantly, causing investors severe harm.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact: Khang & Khang LLP Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
